Now in its third year, the Biotech Outsourcing Strategies (BOS) meeting organized by Bio2Business took place at the Søhuset Conference Centre in Hørsholm, Copenhagen. The focus of this year's event was the demanding and challenging area of chemistry, manufacturing and controls (CMC), and the meeting provided ample opportunity for lively discussion of the key issues surrounding this area. New for the 2010 conference, a biologics-focused lecture stream ran in parallel to the established small molecule stream. Both streams boasted a distinguished panel of keynote speakers who discussed all aspects of CMC from early stage scale-up through late stage clinical development. In addition to the keynote speakers, selected contract research organizations (CROs) gave short presentations on the solutions that they could provide to some of the challenges facing CMC. The meeting attracted more than 150 delegates from leading drug development companies and CRO service providers, and greatly facilitated the forging of new working relationships through pre-arranged one-to-one meetings. Moreover, exhibitions from event sponsors and considerable scheduled networking time over lunch and evening reception further enhanced the highly productive and interactive nature of the meeting.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958568 | PMC |
http://dx.doi.org/10.4161/mabs.2.5.13079 | DOI Listing |
Bioanalysis
December 2022
Future Science Group, London, N3 1QB, UK.
J Med Chem
October 2020
Kodib, LLC, Southampton, Pennsylvania 18966, United States.
Outsourcing has become an integral part of how research and early development (R&D) is executed in biotech companies and large pharmaceutical organizations. Drug discovery organizations can choose from several operational models when partnering with a service provider, ranging from short-term, fee-for-service (FFS)-based arrangements to more strategic full-time-equivalent (FTE)-based collaborations and even risk-sharing relationships. Clients should consider a number of criteria when deciding which contract research organization (CRO) is best positioned to help meet their goals.
View Article and Find Full Text PDFFront Bioeng Biotechnol
June 2019
Biosecure Ltd, Market Rasen, United Kingdom.
The expanding digitization of the biological sciences places greater value on the data generated, information extrapolated and knowledge gained. Failing to protect data will affect a company or country's ability to position itself optimally in the forthcoming fourth industrial revolution. Further, more reliance on automation, distribution, and outsourcing in biotechnology makes its infrastructure a target.
View Article and Find Full Text PDFJ Health Econ
May 2019
EM Lyon Business School & GATE L-SE UMR 5824, France. Electronic address:
We draw from documented characteristics of the biopharmaceutical industry to construct a model where two firms can choose to outsource R&D to an external unit, and/or engage in internal R&D, before competing in a final market. We investigate the distribution of profits among market participants, and the incentives to coordinate outsourcing activities or to integrate R&D and production. Consistent with the empirical evidence, we find that the sign and magnitude of an aggregate measure of direct (inter-firm) and indirect (through the external unit) technological externalities drives the distribution of industry profits, with higher returns to the external unit when involved in development (clinical trials) than in early-stage research (drug discovery).
View Article and Find Full Text PDFBioanalysis
April 2019
Translational Biomarkers & Bioanalysis, Drug Safety & Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!